Results 11 to 20 of about 5,242 (246)

Willingness to pay for new medicines: a step towards narrowing the gap between NICE and IQWiG

BMC Health Services Research, 2020
Background The question of how to set the cost-effectiveness threshold for new, innovative medicines is a matter of ongoing controversy. One prominent proposal suggests that the cost-effectiveness threshold adopted by the U.K.
Afschin Gandjour
doaj   +2 more sources

Different interpretation of additional evidence for HTA by the commissioned HTA body and the commissioning decision maker in Germany: whenever IQWiG and Federal Joint Committee disagree

Health Economics Review, 2019
Background The purpose of this study was to analyse the impact of commissioned addenda by the Federal Joint Committee (FJC) to the HTA body (IQWiG) and their agreement with FJC decisions and to identify potential additional decisive factors of FJC ...
C. M. Dintsios, F. Worm, J. Ruof, M. Herpers   +3 more
doaj   +2 more sources

Imaginary Worlds and Efficiency Frontiers: Should We Abandon the IQWiG Health Technology Assessment Model?

INNOVATIONS in Pharmacy, 2017
The contribution of cost-effectiveness analysis to the pricing of pharmaceuticals in Germany is at best marginal and in many, if not most cases, absent.
Paul C Langley
doaj   +2 more sources

Discrepancies Between Recommendations in Evidence-Based Guidelines for the Management of Obesity in Adolescents and Adults: An Evidence Map. [PDF]

Obes Rev
ABSTRACT Background/Aim The aim of this evidence map is to provide a systematic overview of evidence‐based guidelines for the management of obesity and to highlight discrepancies between recommendations for the pediatric and adult populations. Knowing about these discrepancies may be relevant during the transition from pediatrics to adult healthcare to
Brauchmann J, Laudenbach L, Kapp P, Grummich K, Lischka J, Vanersa N, Rocha EPAA, Ernst G, Meerpohl JJ, Tannen A, Weghuber D, Weihrauch-Blüher S, Wiegand S, Torbahn G.   +13 more
europepmc   +2 more sources

[IQWiG evidence report on psychological consequences of abortion]. [PDF]

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz
Das Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) wurde vom Bundesministerium für Gesundheit beauftragt, bei der Weiterentwicklung der S2k-Leitlinie „Schwangerschaftsabbruch im ersten Trimenon“ zu einer S3-Leitlinie zu ...
Endres D, Gowik J, Tasar A.
europepmc   +2 more sources

Defining Comparators According to IQWiG’s Efficiency-Frontier Method [PDF]

Value in Health, 2020
A. Gandjour
openaire   +3 more sources

Hodenkrebsscreening bei Männern ab 16 Jahren: IQWiG ThemenCheck Health Technology Assessment-Bericht zu medizinischen, ökonomischen, sozialen, ethischen, rechtlichen und organisatorischen Aspekten

Das Gesundheitswesen, 2021
Zusammenfassung Hintergrund Hodenkrebs tritt v. a. bei jungen Männern zwischen 25 und 45 Jahren auf und ist die häufigste Krebserkrankung in diesem Alter.
P. Schnell-Inderst, Anja Laschkolnig, G. Marckmann, Daniel Antony, U. Siebert, Nikolai Mühlberger   +5 more
semanticscholar   +1 more source

Relevance of indirect comparisons in the German early benefit assessment and in comparison to HTA processes in England, France and Scotland [PDF]

, 2014
Early benefit assessment in Germany under the legislative framework of AMNOG (Arzneimittelmarktneuordnungsgesetz) requires direct comparisons of the new drug with appropriate comparators determined by the Federal Joint Committee (G-BA).
Dippel, Franz-Werner, Gasche, David, Lebioda, Andrea, Plantör, Stefan, Theobald, Karlheinz   +4 more
core   +3 more sources

A systematic comparison of different composite measures (DAS 28, CDAI, SDAI, and Boolean approach) for determining treatment effects on low disease activity and remission in rheumatoid arthritis

BMC Rheumatology, 2022
Background Some composite measures for determining the treatment effects of disease-modifying antirheumatic drugs on remission and low disease activity (LDA) in rheumatoid arthritis (RA) may produce misleading results if they include an acute phase ...
Kirsten Janke, Corinna Kiefer, Natalie McGauran, Bernd Richter, Dietmar Krause, Beate Wieseler   +5 more
doaj   +1 more source

Targeted antenatal anti-D prophylaxis for RhD-negative pregnant women: a systematic review

BMC Pregnancy and Childbirth, 2020
Background All non-sensitized Rhesus D (RhD)-negative pregnant women in Germany receive antenatal anti-D prophylaxis without knowledge of fetal RhD status.
Britta Runkel, Gregor Bein, Wiebke Sieben, Dorothea Sow, Stephanie Polus, Daniel Fleer   +5 more
doaj   +1 more source